Cargando…
吉非替尼治疗32例肺腺癌脑转移的临床经验
BACKGROUND AND OBJECTIVE: Brain metastasis was frequent in non-small cell lung cancer (NSCLC) patients with poor prognosis. Gefitinib was an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been used in the treatment of NSCLC. Our study was to evaluate the efficacy and tox...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000113/ https://www.ncbi.nlm.nih.gov/pubmed/26383979 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.05 |
Ejemplares similares
-
培美曲塞治疗全身化疗和吉非替尼治疗失败的肺腺癌32例临床观察
Publicado: (2010) -
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
Publicado: (2013) -
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Publicado: (2013) -
80例晚期NSCLC吉非替尼治疗长于6个月患者的预后因素分析
Publicado: (2010) -
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Publicado: (2011)